靶向肝癌干细胞的治疗策略课件

1、靶向肝癌干细胞的治疗策略22肝癌是我国高发、高致死率的重大疾病手术切除是肝癌患者可能治愈的主要治疗模式术后5年生存率低于11%术后术后两年复发率50%3Xu et al. Carcinogenesis, 2010; Xu et al. Cytotherapy, 2010 Hep-11 : 原发来源Hep-12：复发来源 107细胞 6个月不成瘤 100个细胞 成瘤 非肿瘤干细胞 富含肿瘤干细胞（CSC）4全细胞差减免疫杂交瘤技术Hep-11特异针对Hep-12的单克隆抗体Zhao et al. Cancer Cell, 2013利用复发肝癌细胞模型开展肝癌复发研究策略Hep-12 1B50-1

2、抗体Hep-11Hep-12 51B50-1反应阳性细胞具有肿瘤干细胞特性Zhao et al. Cancer Cell, 2013; 23(4):541-556. 6MarkersTumor formationP1031021B501+/CD133+(A)5/55/54.67E-06 (A vs. B)1B501-/CD133+(B)2/52/50.689 (B vs. C)1B501-/CD133-(C)2/51/51.48E-06 (A vs. C)1B501+/CD13+(D)5/54/52.28E-06 (D vs. E)1B501-/CD13+(E)1/50/51.0 (E vs.

3、 F)1B501-/CD13-(F)1/50/52.28E-06 (D vs. F)1B501+/EpCAM+(G)5/55/58.5E-10 (G vs. H)1B501-/ EpCAM+ (H)2/53/50.11(H vs. I)1B501-/ EpCAM- (I)1/51/58.9E-125 (G vs. I)1B50-1+/CD133+1B50-1-/CD13+1B50-1-/CD13-1B50-1+/CD13+1B50-1-/CD133+1B50-1-/CD133-1B50-1-/EpCAM-1B50-1+/EpCAM+1B50-1-/EpCAM+1B50-1+ subpopula

4、tion is more tumorigenic71B50-1 recognizes 21 (Isofom 5)Voltage-gated calcium channel 21 subunit（Encoded by CACNA2D1）The higher levels of CACNA2D1 predict poor prognosis of HCC patient21 is a LCSC MarkerHan et al. Nature Communications. 2015. 1B50-1 has a therapeutic effect on established tumors of Hep-12400g group vs. IgG group: Inhibition rate of volume=76.3%Inhibition rate of net weight=72.1% 800 g group vs. IgG group: Inhibition rate of volume=87.9%Inhibition rate of n